🇺🇸 FDA
Pipeline program

venglustat GZ402671 - SAR402671, IMIGLUCERASE, venglustat GZ402671 - SAR402671

PDY13949

Phase 2 small_molecule active

Quick answer

venglustat GZ402671 - SAR402671, IMIGLUCERASE, venglustat GZ402671 - SAR402671 for Gaucher disease type 3, Gaucher disease type 1 is a Phase 2 program (small_molecule) at Genzyme Europe B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Genzyme Europe B.V.
Indication
Gaucher disease type 3, Gaucher disease type 1
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials